We are using cookies This website uses cookies in order to offer you the most relevant information. By browsing this website, you accept these cookies.
A confirmatory phase 2 clinical trial is ongoing to assess ceritinib activity in patients with ALK-rearranged NSCLC and brain or leptomeningealmetastases.